Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
16 Apr 24
8-K
Unregistered Sales of Equity Securities
18 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
424B5
Prospectus supplement for primary offering
6 Mar 24
424B5
Prospectus supplement for primary offering
4 Mar 24
8-K
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
4 Mar 24
S-8
Registration of securities for employees
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
18 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
13 Nov 23
8-K
Regulation FD Disclosure
10 Oct 23
8-K
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 23
8-K
Results of Operations and Financial Condition
5 Jun 23
8-K
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
17 May 23
424B5
Prospectus supplement for primary offering
17 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
29 Mar 23
S-8
Registration of securities for employees
17 Mar 23
8-K
Entry into a Material Definitive Agreement
17 Mar 23
424B5
Prospectus supplement for primary offering
17 Mar 23
8-K
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
17 Mar 23
10-K
2022 FY
Annual report
17 Mar 23
10-Q
2022 Q3
Quarterly report
4 Nov 22
8-K
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
4 Nov 22
8-K
Entry into a Material Definitive Agreement
16 Sep 22
424B5
Prospectus supplement for primary offering
15 Sep 22
424B5
Prospectus supplement for primary offering
13 Sep 22
8-K
Regulation FD Disclosure
13 Sep 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
8-K
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
4 Aug 22
8-K
Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
16 Jun 22
Latest ownership filings
4
Jonathan Young
3 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
Catriona Yale
15 Mar 24
4
William Richard White
15 Mar 24
4
Andrew Cheng
15 Mar 24
4
Jonathan Young
15 Mar 24
4
Timothy Rolph
15 Mar 24
SC 13G
GENERAL ATLANTIC, L.P.
15 Mar 24
4
Andrew Cheng
6 Mar 24
4
Catriona Yale
6 Mar 24
4
Jonathan Young
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
Redmile Group, LLC
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
PFIZER INC
14 Feb 24
SC 13G
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G
RTW INVESTMENTS, LP
14 Feb 24
SC 13G/A
Avidity Partners Management LP
13 Feb 24
SC 13G/A
ALKEON CAPITAL MANAGEMENT LLC
13 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Andrew Cheng
3 Jan 24
4
Jonathan Young
29 Dec 23
144
Notice of proposed sale of securities
29 Dec 23
4
Catriona Yale
18 Dec 23
4
William Richard White
18 Dec 23
4
Jonathan Young
18 Dec 23
4
Andrew Cheng
18 Dec 23
4
Timothy Rolph
18 Dec 23
4
William Richard White
12 Dec 23
4
Jonathan Young
12 Dec 23
4
Timothy Rolph
12 Dec 23
4
Patrick Lamy
12 Dec 23
4
Catriona Yale
12 Dec 23
4
G. Walmsley Graham
11 Dec 23